CEACAM5 and non-small cell lung carcinoma: A phase III clinical trial (NCT02187848) investigating combined first-line chemotherapy and immunotherapy for advanced NSCLC patients with high CEACAM5 expression is currently underway, with hopes of clinical benefit.